References
- Cao D, Hou M, Guan YS, et al. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer [Internet]. 2009 Dec 10 [cited 2021 Jul 31]. 9(1): 432. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797529/
- Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. PubMed [Internet]. [cited 2021 Jul 31]. Available from: https://pubmed.ncbi.nlm.nih.gov/16203786/
- Zhao J, Salmon H, Sarntinoranont M. Effect of heterogeneous vasculature on interstitial transport within a solid tumor. Microvasc Res. 2007 May;73(3):224–236.
- Simonsen TG, Gaustad JV, Leinaas MN, et al. High interstitial fluid pressure is associated with tumor-line specific vascular abnormalities in human melanoma xenografts. PLoS One [Internet]. 2012 Jun 29 [cited 2021 Jul 31];7(6):e40006. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386940/
- Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004 Oct;4(10):806–813.
- Skeel RT, and Khleif SN. Handbook of cancer chemotherapy. Hagerstown, MD, USA: Lippincott Williams & Wilkins; 2011. p. 896.
- Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24(3):179–191.
- Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev [Internet]. 2018 May [cited 2021 Jul 31];130:17–38. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130746/
- Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006 Sep;11(17–18):812–818.
- Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. PubMed [Internet]. [cited 2021 Jul 31]. Available from: https://pubmed.ncbi.nlm.nih.gov/19070661/
- Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001 Mar 1;46(1–3):169–185.
- Hollis CP, Weiss HL, Leggas M, et al. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release. 2013 Nov 28;172(1):12–21.
- Torrice M. Does nanomedicine have a delivery problem? ACS Cent Sci. 2016 Jul 27;2(7):434–437.
- The entry of nanoparticles into solid tumours. Nature Materials [Internet]. [cited 2021 Jul 31]. Available from: https://www.nature.com/articles/s41563-019-0566-2
- Kawai M, Higuchi H, Takeda M, et al. Dynamics of different-sized solid-state nanocrystals as tracers for a drug-delivery system in the interstitium of a human tumor xenograft. Breast Cancer Res. 2009;11(4):R43.
- Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007 May 1;13(9):2722–2727.
- Seynhaeve ALB, Dicheva BM, Hoving S, et al. Intact doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro / in vivo live cell imaging. J Control Release. 2013 Nov 28;172(1):330–340.
- Yoo J, Park C, Yi G, et al. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel) [Internet]. 2019 May 8 [cited 2021 Apr 28];11(5). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562917/.
- Estanqueiro M, Amaral M, and Conceição J, et al. Evolution of liposomal carriers intended to anticancer drug delivery: an overview. International Journal of Current Pharmaceutical Research. 2015;6(4): 3–10. ISSN: .
- Schroeder A, Honen R, Turjeman K, et al. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release. 2009 Jul 1;137(1):63–68.
- Hong CW, Libutti SK, Wood BJ. Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. Curr Oncol. 2013 Jun;20(3):e274–277.
- Koning GA, Eggermont AMM, Lindner LH, et al. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res. 2010 Aug;27(8):1750–1754.
- Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010 Jun;11(6):561–570.
- Zhu L, Altman MB, Laszlo A, et al. Ultrasound hyperthermia technology for radiosensitization. Ultrasound Med Biol. 2019 May;45(5):1025–1043.
- Wessalowski R, Schneider DT, Mils O, et al. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Lancet Oncol. 2013 Aug;14(9):843–852.
- Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Research [Internet]. [cited 2021 Aug 1]. Available from: https://cancerres.aacrjournals.org/content/72/21/5566
- Nanoparticle delivery of cancer drugs. Annual Review of Medicine [Internet]. [cited 2021 Aug 1]. Available from: https://www.annualreviews.org/doi/abs/10.1146/annurev-med-040210-162544
- Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Research [Internet]. [cited 2021 Aug 1]. Available from: https://cancerres.aacrjournals.org/content/60/16/4440.short
- Yu M, Guo F, Tan F, et al. Dual-targeting nanocarrier system based on thermosensitive liposomes and gold nanorods for cancer thermo-chemotherapy. J Control Release. 2015;215:91–100.
- Valle SJ, Alzahrani NA, Liauw W, et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol [Internet]. 2016 Jun [cited 2022 Apr 21];7(2):152–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818620/
- Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. PubMed [Internet]. [cited 2021 Aug 1]. Available from: https://pubmed.ncbi.nlm.nih.gov/11156395/
- Funaki K, Fukunishi H, Funaki T, et al. Magnetic resonance-guided focused ultrasound surgery for uterine fibroids: relationship between the therapeutic effects and signal intensity of preexisting T2-weighted magnetic resonance images. Am J Obstet Gynecol. 2007 Feb;196(2):184.e1–6.
- Schmid FA, Schindele D, Mortezavi A, et al. Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: safety outcomes and complications. Urol Oncol. 2020 Apr;38(4):225–230.
- MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. The Lancet Neurology [Internet]. [cited 2021 Aug 1]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS1474-4422(13)700486/fulltext)700486/fulltext
- High-intensity focused ultrasound in the treatment of solid tumours. Nature Reviews Cancer [Internet]. [cited 2021 Aug 1]. Available from: https://www.nature.com/articles/nrc1591
- Frenkel V, Li KCP. Potential role of pulsed-high intensity focused ultrasound in gene therapy. Future Oncol. 2006 2;Feb(1):111–119.
- Staruch R, Chopra R, Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia. 2011;27(2):156–171.
- Henderson TA, Morries LD. Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?. Neuropsychiatr Dis Treat [Internet]. 2015 Aug 21 [cited 2021 Aug 1];11:2191–2208. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552256/
- Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano [Internet]. [cited 2021 Aug 1]. Available from: https://pubs.acs.org/doi/10.1021/nn201010q
- Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Letters [Internet]. [cited 2021 Aug 1]. Available from: https://pubs.acs.org/doi/10.1021/nl050127s
- Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Research [Internet]. [cited 2021 Aug 1]. Available from: https://cancerres.aacrjournals.org/content/69/4/1659
- Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. PubMed [Internet]. [cited 2021 Aug 1]. Available from: https://pubmed.ncbi.nlm.nih.gov/19366797/
- Chen J, Glaus C, Laforest R, et al. Gold nanocages as photothermal transducers for cancer treatment. Small [Internet]. 2010 Apr 9 [cited 2021 Aug 1];6(7):811–817. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035053/
- Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano [Internet]. [cited 2021 Aug 1]. Available from: https://pubs.acs.org/doi/10.1021/nn301135w
- Remote control of ion channels and neurons through magnetic-field heating of nanoparticles. Nature Nanotechnology [Internet]. [cited 2021 Aug 1]. Available from: https://www.nature.com/articles/nnano.2010.125
- Liu X, He Z, Chen Y, et al. Dual drug delivery system of photothermal-sensitive carboxymethyl chitosan nanosphere for photothermal-chemotherapy. Int J Biol Macromol [Internet]. 2020 Nov 15 [cited 2022 Apr 20];163:156–166. Available from: https://www.sciencedirect.com/science/article/pii/S0141813020336448
- Raza A, Hayat U, Rasheed T, et al., “Smart” materials-based near-infrared light-responsive drug delivery systems for cancer treatment: a review. J Mater Res Technol [Internet]. 2019 Jan 1 [cited 2022 Apr 20];8(1):1497–1509. Available from: https://www.sciencedirect.com/science/article/pii/S2238785417307251
- Sasaki A, Kai S, Iwashita Y, et al. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer. 2005 Jan 15;103(2):299–306.
- Swenson CE, Haemmerich D, Maul DH, et al. Increased duration of heating boosts local drug deposition during radiofrequency ablation in combination with thermally sensitive liposomes (ThermoDox) in a porcine model. PLoS One. 2015;10(10):e0139752.
- Principles of and advances in percutaneous ablation. PubMed [Internet]. [cited 2021 Aug 1]. Available from: https://pubmed.ncbi.nlm.nih.gov/21273519/
- Microwave-triggered smart drug release from liposomes co-encapsulating doxorubicin and salt for local combined hyperthermia and chemotherapy of cancer. Bioconjugate Chemistry [Internet]. [cited 2021 Aug 1]. Available from: https://pubs.acs.org/doi/10.1021/acs.bioconjchem.6b00603
- Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005 Oct;25(Suppl 1):S69–83.
- Dewhirst M. Pilot study of external hyperthermia and intravesical mitomycin-C to treat recurrent bladder cancer after resection and standard adjuvant therapy [Internet]. clinicaltrials.gov; Report No.: NCT00734994; 2015 Jun [cited 2022 Apr 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT00734994
- Synthesis of carbon nanotubes by microwave heating: influence of diameter of catalytic Ni nanoparticles on diameter of CNTs. Journal of Materials Chemistry [Internet]. [cited 2021 Aug 1]. Available from: https://pubs.rsc.org/en/content/articlelanding/2014/ta/c3ta13297h
- Yoo JW, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev [Internet]. 2011 Nov 1 [cited 2021 Aug 1];63(14):1247–1256. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X11000780
- Comparison of procedure costs of various percutaneous tumor ablation modalities. PubMed [Internet]. [cited 2021 Aug 1]. Available from: https://pubmed.ncbi.nlm.nih.gov/25174139/
- Zagar TM, Vujaskovic Z, Formenti S, et al. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug;30(5):285–294.
- Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy. [Internet]. [cited 2021 Aug 2]. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092924
- Dou YN, Weersink RA, Foltz WD, et al. Custom-designed laser-based heating apparatus for triggered release of cisplatin from thermosensitive liposomes with magnetic resonance image guidance. J Vis Exp. 2015 Dec;13(106):e53055.
- Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev [Internet]. 2001 Dec 31 [cited 2022 Apr 19];53(3):307–319. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X01002046
- Kokuryo D, Nakashima S, Ozaki F, et al. Evaluation of thermo-triggered drug release in intramuscular-transplanted tumors using thermosensitive polymer-modified liposomes and MRI. Nanomedicine. 2015 Jan;11(1):229–238.
- Lu T, Lokerse WJM, Seynhaeve ALB, et al. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response. J Control Release.2015 Dec 28;220(Pt A):425–437.
- Dos Santos N, Mayer LD, Abraham SA, et al. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta. 2002 Apr 12;1561(2):188–201.
- Lin W, Xie X, Yang Y, et al. Thermosensitive magnetic liposomes with doxorubicin cell-penetrating peptides conjugate for enhanced and targeted cancer therapy. Drug Deliv. 2016 Nov;23(9):3436–3443.
- Santos MA, Goertz DE, Hynynen K. Focused ultrasound hyperthermia mediated drug delivery using thermosensitive liposomes and visualized with in vivo two-photon microscopy. Theranostics. 2017;7(10):2718–2731.
- Centelles MN, Wright M, So PW, et al. Image-guided thermosensitive liposomes for focused ultrasound drug delivery: using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours. J Control Release. 2018 Jun;28(280):87–98.
- van Elk M, van den Dikkenberg JB, Storm G, et al. Preclinical evaluation of thermosensitive poly(N-(2-hydroxypropyl) methacrylamide mono/dilactate)-grafted liposomes for cancer thermochemotherapy. Int J Pharm. 2018 Oct 25;550(1–2):190–199.
- Lyu Y, Xiao Q, Yin L, et al., Potent delivery of an MMP inhibitor to the tumor microenvironment with thermosensitive liposomes for the suppression of metastasis and angiogenesis. Sig Transduct Target Ther [Internet]. 2019 Aug 9 [cited 2021 Aug 2];4(1):1–9. Available from: https://www.nature.com/articles/s41392-019-0054-9
- Wood BJ, Poon RT, Locklin JK, et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol. 2012 Feb;23(2):248–255.e7.
- Tak WY, Lin SM, Wang Y, et al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res. 2018 Jan 1;24(1):73–83.
- Gasselhuber A, Dreher MR, Partanen A, et al. Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivovalidation. Int J Hyperthermia. 2012;28(4):337–348.
- Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer [Internet]. [cited 2021 Aug 2]. Available from: https://finance.yahoo.com/news/celsion-reports-unanimous-independent-data-130000797.html
- Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update. Celsion Corporation [Internet]. [cited 2021 Aug 2]. Available from: https://investor.celsion.com/news-releases/news-release-details/celsion-corporation-reports-second-quarter-2019-financial
- Phase 3 OPTIMA Trial in HCC to Continue to Follow Patients for OS [Internet]. OncLive. [cited 2022 Jan 14]. Available from: https://www.onclive.com/view/phase-3-optima-trial-in-hcc-to-continue-to-follow-patients-for-os
- Lyon PC, Griffiths LF, Lee J, et al. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours. J Ther Ultrasound. 2017;5(1):28.
- Lyon PC, Gray MD, Mannaris C, et al. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. Lancet Oncol [Internet]. 2018 Aug 1 [cited 2021 May 15];19(8):1027–1039. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30332-2/abstract
- Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419–436.
- Bi H, Xue J, Jiang H, et al. Current developments in drug delivery with thermosensitive liposomes. Asian J Pharm Sci [Internet]. 2019 Jul 1 [cited 2021 Aug 2];14(4):365–379. Available from: https://www.sciencedirect.com/science/article/pii/S1818087617307419